Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors.

被引：0

作者：

Konecny, Gottfried E.

Hendrickson, Andrea Elisabeth Wahner

Winterhoff, Boris

Chander, Cinthiya

Bilic, Sanela

Davenport, Simon

Chung, Adrine

Miller, Lei-Lani

Press, Michael F.

Letrent, Stephen P.

Slamon, Dennis J.

机构：

[1] Univ Calif Los Angeles Med Ctr, Santa Monica, CA USA

[2] Mayo Clin, Rochester, MN USA

[3] Univ Minnesota, Div Gynecol Oncol, Minneapolis, MN USA

[4] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA USA

[5] Vanadro LLC, Urbandale, IA USA

[6] Univ Southern Calif, Los Angeles, CA USA

[7] Translat Res Oncol US, Los Angeles, CA USA

[8] TORL Biotherapeut, Culver City, CA USA

[9] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3082

引用

页数：1